Sanxiang Metropolis Daily, February 23 (correspondent Xia Wenhui, all-media reporter Liu Zhendong, Huang Jing) How to deal with "dumb cancer"? Recently, after more than 10 years of deep cultivation, the team of Professor Cao Deliang of the University of South China has successfully developed a new primary liver cancer diagnostic kit "Aldehyde keto reductase 1B10 assay kit (time-resolved fluorescence immunoassay)", and obtained the registration approval of the three types of diagnostic reagents of the State Drug Administration. This is the first liver cancer diagnostic kit in Mainland China with completely independent intellectual property rights, and it is also the world's first liver cancer diagnosis product based on aldehyde and keto reductase 1B10 (AKR1B10).
At present, the widely used clinically widely used serum diagnostic marker for liver cancer is alpha-fetoprotein (AFP). Through large-scale clinical research, Cao Deliang found that AKR1B10 protein as a serum marker of liver cancer, the performance is significantly better than AFP, mainly reflected in three aspects: one is more sensitive, more easy to identify asymptomatic early liver cancer patients; second, more specific, missed diagnosis rate and misdiagnosis rate is lower; third, the time to reflect the change of the disease is 6-7 times faster than AFP, liver cancer patients can learn the surgical effect earlier through AKR1B10 detection after surgery, providing a scientific basis for doctors to develop a reasonable postoperative treatment plan.
Cao Deliang is a 79-level clinical medicine student of Hengyang Medical College (now the University of South China) and is now a high-level talent of the University of South China. In 1995, Cao Deliang discovered a new gene in his research, and he realized that this might be a new field of research, and since then, he has been rooted in this research. He took the lead in cloning and identifying the gene, namely Aldo-keto reductase 1B10 (AKR1B10), and conducted in-depth and systematic research on its biological function, expression regulation, role and mechanism in tumors, and found that AKR1B10 can become a liver cancer marker, which is used in liver cancer screening, auxiliary diagnosis and monitoring. In the field of AKR1B10 research, Professor Cao Deliang has obtained 4 invention patents and published 31 high-level SCI papers, which is a leading position in the world.
The three types of diagnostic reagents approved this time are the highest classification of in vitro diagnostic reagents in mainland China, and the requirements are also the most stringent, and obtaining the registration approval means that it can be directly applied to the clinic. "This is a very promising diagnostic product, we will continue to expand clinical research, accumulate more AKR1B10 for liver cancer screening, early diagnosis, assessment of the condition, monitoring recurrence and other aspects of the data, and constantly optimize and upgrade the kit, serve healthy China, healthy Hunan, benefit the people and society." Cao Deliang said firmly.
According to the data released by GLOBOCAN in 2018, the number of new cases of liver cancer in the world reached 841,000, ranking 6th in malignant tumors and 782,000 deaths, ranking 2nd in malignant tumors. Liver cancer is particularly high in the mainland, with 466,000 new cases and 422,000 deaths, accounting for 55.4% and 53.9% of the world's total, respectively, ranking 4th for common malignancies and 2nd for tumoric causes of death. Cao Deliang pointed out that the incidence of liver cancer is high, the mortality rate is high, the incidence is hidden, and early diagnosis and early treatment are the keys to improving the survival of patients. It will be committed to establishing an engineering research center for early diagnosis and early treatment of liver cancer, continue to explore and strive to realize the early diagnosis and early treatment of liver cancer, provide help for more liver cancer patients, and realize scientific research to serve the country.